\n
<\/p>\n
Sean A. Power, the Chief Financial Officer of TG Therapeutics, Inc. (NASDAQ:), recently executed a series of stock sales amounting to $629,382, according to a recent SEC filing. The transactions, which took place on January 3 and January 6, involved the sale of 11,337 and 10,021 shares of common stock, respectively. The shares were sold at prices ranging from $28.534 to $30.294 per share. According to InvestingPro<\/a> data, TGTX currently trades near $28, with analyst price targets ranging from $10 to $55, reflecting the stock’s notable volatility.<\/p>\n These sales were conducted automatically to cover tax obligations related to the vesting of restricted stock, as per the company’s corporate policies. Following these transactions, Power retains ownership of 660,611 shares of TG Therapeutics common stock. InvestingPro<\/a> analysis shows the company maintains impressive gross profit margins of 88.31% and has a market capitalization of $4.03 billion. Subscribers can access 12 additional ProTips and a comprehensive Pro Research Report for deeper insights into TGTX’s financial health and market position.<\/p>\n In other recent news, TG Therapeutics has seen a surge in its third-quarter revenues, reporting an impressive $83.9 million, exceeding both H.C. Wainwright’s estimate of $76.7 million and the consensus of $81.7 million. This led H.C. Wainwright to raise its price target for TG Therapeutics from $49.00 to $55.00. The company’s GAAP earnings per share for the quarter were $0.02, falling short of the estimated $0.04, yet on a non-GAAP basis, the EPS was $0.10, aligning with predictions.<\/p>\n TG Therapeutics’ research and development expenses increased to $17.1 million, and selling, general, and administrative expenses rose to $33.2 million. The company has $341.0 million in cash on hand as of September 30, 2024. H.C. Wainwright projects TG Therapeutics’ full-year 2024 revenues to be $317.1 million with a GAAP EPS of $0.07 and a non-GAAP EPS of $0.34.<\/p>\n Amid these recent developments, TG Therapeutics reported substantial growth in its third-quarter earnings call, with US net sales of its flagship product, BRIUMVI, reaching $83.3 million. This marks a significant 230% year-over-year growth and a 15% increase from the previous quarter, prompting the company to raise its full-year sales guidance for BRIUMVI to between $300 million and $305 million.<\/p>\n Furthermore, TG Therapeutics is exploring a 30-minute infusion method and developing a subcutaneous version of BRIUMVI, with trials expected to initiate in 2024. The company aims for BRIUMVI to become a blockbuster brand and plans to expand patient outreach efforts and investments in 2025.<\/p>\n This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.<\/em><\/p>\n<\/div>\n